Compare · LBRX vs NVO
LBRX vs NVO
Side-by-side comparison of LB Pharmaceuticals Inc (LBRX) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both LBRX and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $215.46B, about 136.9x LBRX ($1.57B).
- NVO has been more active in the news (9 items in the past 4 weeks vs 5 for LBRX).
- NVO has more recent analyst coverage (25 ratings vs 8 for LBRX).
- Company
- LB Pharmaceuticals Inc
- Novo Nordisk A/S
- Price
- $48.69+1.16%
- $48.65+3.65%
- Market cap
- $1.57B
- $215.46B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2025
- News (4w)
- 5
- 9
- Recent ratings
- 8
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest LBRX
- SEC Form 424B3 filed by LB Pharmaceuticals Inc
- SEC Form 10-Q filed by LB Pharmaceuticals Inc
- LB Pharmaceuticals Inc filed SEC Form 8-K: Results of Operations and Financial Condition
- LB Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update
- SEC Form 4 filed by Large owner Deep Track Biotechnology Master Fund, Ltd.
- SEC Form 424B3 filed by LB Pharmaceuticals Inc
- LB Pharmaceuticals Inc filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Regulation FD Disclosure
- LB Pharmaceuticals Announces $150 Million Private Placement
- SEC Form 424B3 filed by LB Pharmaceuticals Inc
- SEC Form 8-K filed by LB Pharmaceuticals Inc
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- A New Category Is Forming in Medical Aesthetics. Independent Research Has Started Sizing It.
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo Nordisk A/S downgraded by Berenberg
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S